ClinicalTrials.Veeva

Menu
R

Revival Research | Doral, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Vibegron
ASN002
SCD-044
Upadacitinib
PF-07275315
SHR-1314
ABP 501
LY3454738
Humira®
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 15 total trials

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA)

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Active, not recruiting
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

The purpose of this study is to evaluate the efficacy of guselkumab compared to an inactive drug in participants with low body surface area moderate...

Active, not recruiting
Moderate Plaque Psoriasis
Drug: Placebo
Drug: Guselkumab

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Active, not recruiting
Moderate to Severe Plaque Psoriasis
Drug: Placebo
Drug: SCD-044_Dose 3

Trial sponsors

AbbVie logo
Amgen logo
A
Sun Pharma logo
U
Hengrui Medicine logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Moderna logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems